Promimic's Groundbreaking Results on HAnano Surface Development
Karolinska Development AB is proud to spotlight its portfolio company Promimic, which has recently achieved promising outcomes in its research aimed at combatting bacterial growth on its innovative implant surface called HAnano Surface. This significant advancement underscores Promimic's commitment to enhancing the performance of orthopedic and dental implants, an area where bacterial infections pose serious risks to patient health.
According to the findings published in the Journal of Functional Biomaterials, Promimic has observed a substantial reduction in bacterial growth linked to the HAnano Surface. In previous studies, the company had already noted a decrease in bacterial adhesion. However, this latest research marks a notable step forward as it highlights that the HAnano Surface not only reduces adhesion but also actively discourages growth, which is a critical factor in preventing infections associated with implants.
Understanding the Importance of Reduced Bacterial Growth
The current research indicates that the surface holds a bacteriostatic effect, meaning that it prevents bacteria from proliferating without killing them outright. This is crucial as it helps inhibit the development of bacterial resistance—an increasingly concerning issue in modern medicine.
The study's outcomes are particularly impressive, revealing reductions in bacterial activity between 33% and 46% for two significant strains: S. epidermidis and P. aeruginosa. These bacterial strains are frequently implicated in implant infections and pose substantial threats, especially in the fields of dental and orthopedic surgery.
CEO Insights and Implications for Healthcare
"Bacterial infections linked to dental and orthopedic implants are a major challenge in healthcare today. The need for implants that promote healing while reducing the risk of bacterial growth is more urgent than ever," stated Viktor Drvota, CEO of Karolinska Development. He added that the progress made by Promimic showcases the essential benefits that advanced surface modifications can bring to implant procedures, ultimately benefiting both healthcare providers and patients alike.
Promimic's Innovative HAnano Surface Technology
Promimic's HAnano Surface is a proprietary, nanometer-thin surface treatment that significantly enhances the integration and healing process of orthopedic and dental implants into bone tissue. This cutting-edge technology has been successfully applied to over 1.8 million implants globally, demonstrating its vast potential and reliability in clinical settings.
Karolinska Development holds a 14% stake in Promimic through KDev Investments. This investment reflects the company's strategy to support innovations that aim to solve critical medical challenges and improve patient outcomes.
Looking Ahead: Future Prospects for Promimic
As Promimic continues to advance its HAnano Surface technology, the company is positioned to lead the field in implant development. The findings not only enhance its product offerings but also pave the way for greater partnerships within the healthcare sector looking to leverage these advancements.
For those who wish to know more about Promimic's groundbreaking research and the implications for the medical industry, CEO Viktor Drvota can be contacted at +46 73 982 52 02 or via email at viktor.drvota@karolinskadevelopment.com. Additionally, Johan Dighed, General Counsel and Deputy CEO, can be reached at +46 70 207 48 26 or johan.dighed@karolinskadevelopment.com.
Frequently Asked Questions
What is the HAnano Surface technology?
The HAnano Surface is a unique nanometer-thin treatment designed to enhance the integration and healing of dental and orthopedic implants.
What are the benefits of reduced bacterial growth on implants?
Reduced bacterial growth decreases the risk of infections associated with implants, ultimately promoting better healing and outcomes for patients.
What did the recent studies show regarding bacterial reduction?
The studies showed a reduction in bacterial growth between 33-46% on important bacterial strains, improving the effectiveness of the surface treatment.
How does Karolinska Development support Promimic?
Karolinska Development supports Promimic through investment and strategic guidance to help advance its innovative technologies in the medical field.
Who can I contact for more information about Promimic?
For more details, you can contact Viktor Drvota or Johan Dighed using the provided contact information.
